Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Hydrocortisone Pump in Children with CAH
NCT03718234Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Jan 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hydrocortisone in congenital adrenal hyperplasia (CAH), sponsored by University of Minnesota. Primary endpoints: Cortisol Exposure at 14 weeks and 17-hydroxyprogesterone Exposure at 14 weeks. Started Jan 2019; status: completed.
02
Drugs
hydrocortisone
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT03718234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718234.